The Australia and New Zealand cutaneous T-cell lymphoma (CTCL) market size is expected to grow at a CAGR of 11.3% during the forecast period of 2024-2032, driven by the increasing incidence of the condition across the region, along with a surge in research activities to offer personalized solutions.